Overview

Chronic inflammation driven by elevated interleukin-11 (IL-11) is a critical underlying cause of tissue scarring and cancer, worsening the disease outcomes over time. Current anti-inflammatory options fall short, offering limited control over IL-11 and failing to stop its persistent buildup at injury sites. With no natural solutions available to reliably lower IL-11, this innovation fulfills the urgent demand for a targeted, sustainable anti-inflammatory agent—providing a new path to ease the burden of chronic, hard-to-treat diseases.

The Opportunity

Developed by OSU researchers, this breakthrough introduces a proprietary class of advanced blueberry polyphenols shown to strongly suppress disease-driving IL-11 production, helping to prevent harmful inflammation from progressing into lasting tissue damage and cancer. Offering a natural and stable solution, these modified extracts can enable industry leaders to overcome current therapy limits and deliver powerful, clean-label products that meet the demands of today’s healthcare market.

Patents: Provisional filed

Seeking: Partnership

Transform Your Product Portfolio

Position your brand at the forefront of health innovation with this science-driven natural health solution. As regulatory and consumer expectations evolve, this technology can empower you to launch differentiated products to offer modern relief from inflammation-driven degenerative diseases and transform holistic wellness.

Connect with us today to explore licensing and partnership opportunities and add this next-generation nature-powered health solution to your portfolio.